Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1390872

Comparative Efficacy of Six Programmed Cell Death Protein-1 Inhibitors as First-Line Treatment for Advanced Non-small Cell Lung Cancer: A Multicenter Retrospective Cohort Study

Provisionally accepted
Siyuan Chen Siyuan Chen 1Tao Li Tao Li 1Wenyu Yang Wenyu Yang 2Wang Ting Wang Ting 2Yuhui Qin Yuhui Qin 1Zhijuan Du Zhijuan Du 1*Yanan Li Yanan Li 3*Pengfei Cui Pengfei Cui 2Yi Hu Yi Hu 2*Zhefeng Liu Zhefeng Liu 2*
  • 1 Medical School of Chinese PLA, Beijing, China
  • 2 Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
  • 3 Department of Medical Oncology, The Third Medical Center of PLA General Hospital, Beijing, China

The final, formatted version of the article will be published soon.

    The purpose of this study was to assess the comparative efficacy of six programmed cell death-1 inhibitors (nivolumab, pembrolizumab, sintilimab, tislelizumab, toripalimab, and camrelizumab) that have been used as first-line therapy for Chinese patients with advanced non-small cell lung cancer (NSCLC), which remains unclear. We determined the differences in efficacy by observing patient survival data, with the goal of informing future treatment options. Retrospective data analysis from June 2015 to April 2023 included 913 patients across six groups: nivolumab (123, 13.5%), pembrolizumab (421, 46.1%), sintilimab (239, 26.1%), tislelizumab (64, 7.0%), toripalimab (39, 4.3%), and camrelizumab (27, 3.0%). The median progression-free survival (PFS) for each group was 16.0, 16.1, 18.4, 16.9, 23.7, and 12.8 months, and the median overall survival (OS) was 33.7, 36.1, 32.5, not reached, 30.9, and 46.0 months for the nivolumab, sintilimab, pembrolizumab, tislelizumab, toripalimab, and camrelizumab groups, respectively. While differences existed in the objective response rates among groups (P<0.05), there were no significant differences (all P>0.05) in PFS or OS. The findings suggest comparable efficacy among these PD-1 inhibitors for NSCLC treatment, underscoring their collective suitability and aiding treatment decisions.

    Keywords: comparison, efficacy, Non-small cell lung cancer, PD-1 inhibitors, Long-term survival

    Received: 24 Feb 2024; Accepted: 02 May 2024.

    Copyright: © 2024 Chen, Li, Yang, Ting, Qin, Du, Li, Cui, Hu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zhijuan Du, Medical School of Chinese PLA, Beijing, China
    Yanan Li, Department of Medical Oncology, The Third Medical Center of PLA General Hospital, Beijing, China
    Yi Hu, Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China
    Zhefeng Liu, Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.